Skip to main content

Angiodynamics - Fundamentalanalyse - Jahresbericht / Bilanz / Geschäftsbericht

Angiodynamics (ISIN: US03475V1017, WKN: A0B9A5) Kursdatum: 21.07.2017 Kurs: 15,650 USD
Beschreibung Daten
Symbol ANGO
Marktkapitalisierung 565.925.888,00 USD
Land Vereinigte Staaten von Amerika
Indizes NASDAQ Comp.
Sektor Gesundheitswesen
Rohdaten nach US GAAP in Millionen USD
Aktiensplits
Internet
Letztes Bilanz Update 01.08.2016

Fundamentaldaten

Fundamental Verhältnisse errechnet am: 21.07.2017
KFCV KCV DIV Rendite GKR EKQ KGV KUV KBV
13,10 12,52 0,00% -5,81 73,09 -12,93 1,60 1,03

Firmenbeschreibung

QUARTERLY INFORMATION (unaudited)Quarterly results of operations during the fiscal years ended May 31, 2016 and 2015 are as follows:  2016 Firstquarter Secondquarter Thirdquarter Fourthquarter (in thousands, except per share data)Net sales$83,753 $89,284 $87,434 $93,419Gross profit43,371 45,884 43,534 41,527Net income (loss)(775) (334) 594 (43,075)Earnings (loss) per common share       Basic(0.02) (0.01) 0.02 (1.19)Diluted(0.02) (0.01) 0.02 (1.19)  2015 Firstquarter Secondquarter Thirdquarter Fourthquarter (in thousands, except per share data)Net sales$87,091 $92,149 $86,597 $90,697Gross profit45,964 46,828 37,673 45,331Net income (loss)284 1,069 (4,153) (588)Earnings (loss) per common share       Basic0.01 0.03 (0.12) (0.02)Diluted0.01 0.03 (0.12) (0.02)The data in the schedules above has been intentionally rounded to the nearest thousand and therefore the quarterly     amounts may not sum to the full year amounts. We made adjustments to correct immaterial errors within this selected financial data. For a detailed explanation of these adjustments, please refer to Note R, "Immaterial Error Corrections". Three months ended February 29, 2016 As previously reported Adjustments As revisedNet sales$87,384 $50 $87,434Gross profit43,484 50 43,534Sales and marketing20,301 654 20,955General and administrative6,784 117 6,901Total operating expenses40,797 771 41,568Operating income 2,687 (721) 1,966Other expense(868) 654 

Firmenstrategie

RevenueRecognitionPolicyTextBlock

Revenue Recognition


We recognize revenue when the following four criteria has been met: (i) persuasive evidence that an arrangement exists; (ii) the price is fixed or determinable; (iii) collectability is reasonably assured; and (iv) product delivery has occurred or services have been rendered. We recognize revenue, net of sales taxes assessed by any governmental authority, as products are shipped, based on shipping terms, and when title and risk of loss passes to customers. We negotiate shipping and credit terms on a customer-by-customer basis and products are shipped at an agreed upon price. All product returns must be pre-approved by us and customers may be subject to a 20% restocking charge. To be accepted, a returned product must be unadulterated, undamaged and have at least twelve months remaining prior to its expiration date. Charges for discounts, returns, rebates and other allowances are recognized as a deduction from revenue on an accrual basis in the period in which the revenue is recorded. The accrual for product returns, discounts and other allowances is based on the company’s history.


Shipping and handling costs, associated with the distribution of finished products to customers, are recorded in costs of goods sold and are recognized when the related finished product is shipped to the customer. Amounts charged to customers for shipping are recorded in net sales.

SegmentReportingDisclosureTextBlock

SEGMENTS AND GEOGRAPHIC INFORMATION

Segment information

We consider our business to be a single segment entity related to the development, manufacture and sale on a global basis of medical devices for vascular access, surgery, peripheral vascular disease and oncology. Our chief operating decision maker (CEO) evaluates the various global product portfolios on a net sales basis. Executives reporting in to the CEO include those responsible for operations and supply chain management, research and development, sales, franchise marketing and certain corporate functions. The CEO evaluates profitability, investment and cash flow metrics on a consolidated worldwide basis due to shared infrastructure and resources.

Total sales by product category are summarized below (in thousands):

 

 
Year Ended
 
May 31,
2016
 
May 31,
2015
 
May 31,
2014
Net sales by Product Category
 
 
 
 
 
Peripheral Vascular
$
202,780

 
$
192,713

 
$
192,626

Vascular Access
99,375

 
107,754

 
106,394

Oncology/Surgery
48,895

 
51,890

 
49,360

Supply Agreement
2,840

 
4,177

 
6,045

Total
$
353,890

 
$
356,534

 
$
354,425


Geographic information

Total sales for geographic areas are summarized below (in thousands):

 

 
Year Ended
 
May 31,
2016
 
May 31,
2015
 
May 31,
2014
Net sales by Geography
 
 
 
 
 
United States
$
283,519

 
$
280,611

 
$
280,161

International
67,531

 
71,746

 
68,219

Supply Agreement
2,840

 
4,177

 
6,045

Total
$
353,890

 
$
356,534

 
$
354,425


For fiscal years 2016, 2015 and 2014, International sales as a percentage of total net sales were 19%, 20% and 19%, respectively. Sales to any one country outside the U.S., as determined by shipment destination, did not comprise a material portion of our net sales in any of the last three fiscal years. 99% of our total assets are located within the United States.

EarningsPerSharePolicyTextBlock

EARNINGS PER SHARE

Basic earnings per share are based on the weighted average number of common shares outstanding without consideration of potential common stock. In addition, diluted earnings per share include the dilutive effect of potential common stock consisting of stock options, restricted stock units and performance stock units, provided that the inclusion of such securities is not anti-dilutive. In periods with a net loss, stock options and restricted stock units are not included in the computation of basic loss per share as the impact would be anti-dilutive.

The following table reconciles basic to diluted weighted average shares outstanding for the years ended May 31, 2016, 2015 and 2014:

 
2016
 
2015
 
2014
Basic
36,161,383

 
35,683,139

 
35,135,689

Effect of dilutive securities

 

 
304,161

Diluted
36,161,383

 
35,683,139

 
35,439,850

 
 
 
 
 
 
Securities excluded as their inclusion would be anti-dilutive
3,277,037

 
2,862,414

 
2,347,426